VRAX Kapitalisasi Akuntansi Virax Biolabs

As an authoritative player in early virus detection, Virax Biolabs Group (VRAX) develops precise immune systems, generating revenue through the sale of diagnostic kits for influenza and hepatitis monitoring. This chart reflects current share prices fixed at 0.02. Meanwhile, the brand's production capacities are operating normally, undergoing technical modernization to launch updated test series.

VRAX Kapitalisasi Buku Virax Biolabs (28.04.2023 - 28.10.2026)

Virax Biolabs - rincian analitis lan metrik utama (VRAX)

- rega lan prakiraan konsensus rega:

Rega saham Virax Biolabs Corp|VRAX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Virax Biolabs Group Limited|VRAX - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Virax Biolabs|VRAX - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku viraxbiolabs.com|VRAX - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Utang marang Ekuitas Virax Biolabs Group|VRAX - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Virax Biolabs Group Limited|VRAX - Utang perusahaan|Rasio utang marang nilai buku Virax Biolabs Group Limited|VRAX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Virax Biolabs

Analisis dhasar perusahaan:VRAX - Virax Biolabs Corp

Book value capitalization represents a daily revaluation of net assets, capturing the real value of equity under inflationary pressure. The current value of 0.02 for the firm's book capital reflects the financial stability of Virax Biolabs Group (VRAX), which is critical for scaling the diagnostic laboratory network and expanding test distribution into emerging markets.

Analisis pesaing Virax Biolabs Group